Imatinib Koanaa (Imatinib)

Imatinib acts on malignant cells that depend on BCR‑ABL, c‑KIT or PDGFR signaling, providing targeted therapy for several hematologic and solid tumours.

• Chronic Myeloid Leukemia (CML): helps achieve and maintain cytogenetic and molecular remission.
• Gastrointestinal Stromal Tumor (GIST): reduces tumor growth and prolongs progression‑free survival.
• Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

• Imatinib selectively inhibits the tyrosine kinase activity of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptors (PDGFR). By blocking these enzymes, it interrupts downstream signaling pathways that drive uncontrolled proliferation and survival of malignant cells, leading to cell cycle arrest and apoptosis in responsive tumors.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often of the ankles.
• Muscle cramps: intermittent tightening of skeletal muscles.
• Fatigue: generalized lack of energy.
• Diarrhea: loose stools, sometimes watery.
• Rash: mild skin eruptions.

Serious or Rare Side Effects

• Neutropenia: significant reduction in white blood cells.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: signs of reduced heart function.
• Severe bleeding: hemorrhage due to platelet dysfunction.
• Interstitial lung disease: inflammatory lung changes.
• Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

Patients should be monitored for safety and efficacy throughout therapy.

• Blood counts: perform regular CBC to detect neutropenia or anemia.
• Liver function: assess hepatic enzymes before and during treatment.
• Drug interactions: avoid strong CYP3A4 inhibitors unless medically necessary.
• Pregnancy and lactation: discuss risks with a healthcare professional; use only if benefits outweigh potential harm.
• Renal impairment: adjust dosing in severe kidney disease as advised by prescriber.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib exposure.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.
• Antacids containing aluminum or magnesium: can lower absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Digoxin: possible increase in serum concentration.
• Proton pump inhibitors: may modestly affect bioavailability.
• Vaccines (live attenuated): assess risk of reduced immune response.
• Herbal supplements (e.g., St. John’s wort): potential CYP3A4 induction.